Search results for "Squamous cell"

showing 10 items of 469 documents

Computerised tomography and magnetic resonance imaging of laryngeal squamous cell carcinoma: A practical approach

2017

Squamous cell carcinoma is the most common head and neck cancer. This review describes the state-of-the-art computerised tomography and magnetic resonance imaging protocols of the neck and the normal larynx anatomy, and provides a practical approach for the diagnosis and staging of laryngeal squamous cell carcinoma.

Larynxsquamous cell carcinomamedicine.medical_specialtyRadiology Nuclear Medicine and ImagingSensitivity and Specificity030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineComputerised tomographymedicineHumansBasal cellLaryngeal NeoplasmsNeoplasm Stagingmedicine.diagnostic_testbusiness.industryComputerised tomography; magnetic resonance imaging; squamous cell carcinoma; Radiology Nuclear Medicine and Imaging; Neurology (clinical)Head and neck cancerMagnetic resonance imagingGeneral MedicineLaryngeal squamous cell carcinomamedicine.diseaseMagnetic Resonance Imagingstomatognathic diseasesmedicine.anatomical_structure030220 oncology & carcinogenesisCarcinoma Squamous CellRadiologyTomographyNeurology (clinical)LarynxHead and Neck ImagingbusinessTomography X-Ray Computed
researchProduct

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.

2011

International audience; BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) who have been exposed to thiopurines might have an increased risk of skin cancer. We assessed this risk among patients in France. METHODS: We performed a prospective observational cohort study of 19,486 patients with IBD, enrolled from May 2004 to June 2005, who were followed up until December 31, 2007. The incidence of nonmelanoma skin cancer (NMSC) in the general population, used for reference, was determined from the French Network of Cancer Registries. RESULTS: Before the age of 50 years, the crude incidence rates of NMSC among patients currently receiving or who previously received thiopurines wer…

MaleSkin NeoplasmsCohort Studies0302 clinical medicineRisk FactorsMedicineProspective StudiesProspective cohort studyAged 80 and overeducation.field_of_studyThiopurine methyltransferasebiology[CHIM.ORGA]Chemical Sciences/Organic chemistryIncidenceHazard ratioGastroenterologyMiddle Aged3. Good health030220 oncology & carcinogenesisCarcinoma Squamous Cell030211 gastroenterology & hepatologyFemaleFranceImmunosuppressive AgentsCohort studyAdultmedicine.medical_specialtyUltraviolet RaysPopulation03 medical and health sciences[ CHIM.ORGA ] Chemical Sciences/Organic chemistryInternal medicineHumansRisk factoreducationAgedProportional Hazards ModelsHepatologybusiness.industryOdds ratiomedicine.diseaseInflammatory Bowel DiseasesSurgeryCarcinoma Basal CellPurinesbiology.proteinSkin cancerbusinessSunscreening AgentsFollow-Up Studies
researchProduct

The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral s…

2012

Growth and metastasis of solid tumors requires induction of angiogenesis to ensure the delivery of oxygen, nutrients and growth factors to rapidly dividing transformed cells. Through either mutations, hypoxia generated by cytoreductive therapies, or when a malignancy outgrows its blood supply, tumor cells undergo a change from an avascular to a neovascular phenotype, a transition mediated by the hypoxia-inducible factor (HIF) family of transcriptional regulators. Vascular endothelial growth factor (VEGF) is one example of a gene whose transcription is stimulated by HIF. VEGF plays a crucial role in promoting tumor growth and survival by stimulating new blood vessel growth in response to suc…

Vascular Endothelial Growth Factor AAngiogenesisSEMA4DSemaphorinsBiologyArticleVEGForal squamous cell carcinomasemaphorin 4Dhypoxia-inducible factorMicechemistry.chemical_compoundSemaphorinAntigens CDSettore BIO/10 - BiochimicaAnimalsHumansCells CulturedCell ProliferationNeovascularization PathologicNeoplasms ExperimentalCell BiologyOxygen tensionVascular endothelial growth factorVascular endothelial growth factor AHEK293 CellsHIF1AHypoxia-inducible factorschemistryImmunologyCarcinoma Squamous CellCancer researchMouth NeoplasmsExperimental Cell Research
researchProduct

Cetuximab in squamous cell head and neck carcinomas.

2007

The epidermal growth factor receptor (EGFR) antagonist, cetuximab, has recently been shown to enhance the effects of radiotherapy, and reports to date indicate that this effect occurs without any change in the pattern and severity of toxicity usually associated with head and neck radiation and/or chemotherapy (CT) administration. Moreover, several studies have reported that the expression of EGFR is strongly linked to poor outcome in patients undergoing therapy. Therefore, the presence of the EGFR in almost all cases of head and neck carcinoma offers a new therapeutic opportunity to most patients. In this paper, we report a review of the major studies dealing with the use of cetuximab in ad…

Oncologymedicine.medical_specialtyRadiation-Sensitizing Agentsmedicine.medical_treatmentCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedClinical Trials Phase II as TopicInternal medicinemedicineCarcinomaAnimalsHumansEpidermal growth factor receptorSquamous epithelial cellCetuximabbiologyClinical Trials Phase I as Topicbusiness.industryHead and neck cancerAntibodies MonoclonalHematologymedicine.diseaseHead and neck squamous-cell carcinomaChemotherapy regimenRadiation therapyneck carcinomasmedicine.anatomical_structureOncologyHead and Neck Neoplasmsbiology.proteinCarcinoma Squamous CellNeoplasm Recurrence Localbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

A pioneering epidemiological study investigating the incidence of squamous cell carcinoma of tongue in a Portuguese population

2012

Objective: The purpose of this study was to investigate the incidence of squamous cell carcinoma (SCC) of the anterior two thirds of the tongue in a population living in central and southern Portugal, all treated at Portuguese Institute of Oncology of Lisbon, Francisco Gentil (IPOLFG). Study Design: This study was a retrospective review of all patients who had a histopathological diagnosis of SCC of the anterior two thirds of the tongue and had been treated in the Head and Neck Surgery Unit at the IPOLFG (Lisbon, Portugal), between 1st January 2001 and 31st December 2009. The risk factors evaluated were: gender; age; alcohol consumption; tobacco use; prosthesis use and the carcinoma site. R…

AdultMalemedicine.medical_specialtyCancer cellsPopulationYoung AdultTongueEpidemiologyCarcinomamedicineHumansTongue NeoplasmeducationGeneral DentistryAgedRetrospective StudiesAged 80 and overMoutheducation.field_of_studyOral Medicine and PathologyPortugalPortuguesebusiness.industryIncidenceBocaIncidence (epidemiology)Retrospective cohort studyMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseTongue NeoplasmsPortuguesosSurgerymedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellEtiologyResearch-ArticleFemaleCèl·lules cancerosesSurgerybusinessDemographyMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Expression of clec9a in the oral cancer microenvironment. A preliminary immunohistochemical pilot study

2021

Background The search for treatments to improve cancer survival has led to the emergence of immunotherapy and the study of the tumour microenvironment existing in neoplasms. This preliminary study aims to understand the clinical and pathological relationship of clec9a expression in oral cancer and to explore survival models for future studies. Material and methods: Immunohistochemical study that included 26 patients with a diagnosis of oral squamous cell carcinoma (OSCC) in mobile tongue and floor of the mouth. Clinical and histopathological variables were recorded, and the biomarkers clec9a for dendritic cells and CD8 and CD4 for lymphocytes were used. Results Clec9a was expressed in 58% o…

Oncologymedicine.medical_specialtymedicine.medical_treatmentPilot ProjectsInternal medicineOral Cancer and Potentially malignant disordersmedicineCarcinomaTumor MicroenvironmentHumansLectins C-TypepainGeneral DentistryPathologicalSurvival analysisUNESCO:CIENCIAS MÉDICASMouth neoplasmTumor microenvironmentbusiness.industryResearchquestionnaireCancerpsychometric validationImmunotherapymedicine.diseasePrognosisstomatognathic diseasesOtorhinolaryngologydisabilityHead and Neck NeoplasmsReceptors MitogenCarcinoma Squamous CellImmunohistochemistrySurgeryMouth Neoplasmshead and neck cancerbusiness
researchProduct

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer p…

2011

Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial- growth-factor, with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results from a dose/finding phase I trial in NSCLC patients, demonstrated the anti-angiogenic effects and toxicity of a newest bevacizumab-based combination with fractioned cisplatin and daily oral etoposide. We designed a phase II trial to evaluate in advanced NSCLC patients the antitumor activity and the safety of this novel regimen. In particular, 45 patients (36 males and 9 females), with a mean age of 54 years, an ECOG ≤2, stage III B/IV and NSCLC (28 adenocarcinomas, 11 squamous-cell carcinomas, 2 large-cell carcin…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsBevacizumabDose-dense chemotherapyAdenocarcinomaNSCLCAntibodies Monoclonal HumanizedDrug Administration ScheduleInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsDose/dense-metronomic-chemotherapymedicineHumansLung cancerAgedEtoposideNeoplasm StagingPharmacologyCisplatinbusiness.industryCancerAntibodies MonoclonalmPEBev regimenMiddle Agedmedicine.diseaseVEGFBevacizumabRegimenOncologyToxicityCarcinoma Squamous CellMolecular MedicineEvery Three WeeksCarcinoma Large CellFemaleCisplatinbusinessmedicine.drugCancer biologytherapy
researchProduct

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multice…

2020

Half of patients newly diagnosed with esophageal squamous cell cancer (ESCC) have metastatic disease (mESCC) and therefore a poor prognosis. Furthermore, half of patients with initial loco-regional disease present disease recurrence after surgery and/or chemoradiation. In mESCC, the recommended first-line treatment combines 5-fluorouracil and cisplatin, although this has not been validated by a phase III trial. Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy. Several molecules have been evaluated in phase I/II trials or retrospective studies (docetaxel, paclitaxel and irinotecan) but…

Oncologymedicine.medical_specialtyEsophageal NeoplasmsPaclitaxel[SDV]Life Sciences [q-bio]medicine.medical_treatmentEsophageal cancerPhases of clinical researchIrinotecan03 medical and health scienceschemistry.chemical_compoundClinical Trials Phase II as Topic0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMulticenter Studies as TopicComputingMilieux_MISCELLANEOUSRandomized Controlled Trials as Topic030304 developmental biologyCisplatin0303 health sciencesChemotherapyHepatologyPerformance statusbusiness.industryGastroenterologyEsophageal cancermedicine.disease3. Good healthSurvival RateIrinotecanPaclitaxelchemistryDocetaxel030220 oncology & carcinogenesisDisease ProgressionQuality of LifeSquamous cell cancerEsophageal Squamous Cell CarcinomaFluorouracilFranceNeoplasm Recurrence Localbusinessmedicine.drugDigestive and Liver Disease
researchProduct

Detection of laryngeal squamous cell carcinoma in a context of acrokeratosis paraneoplastica: Case report

2018

Background: Acrokeratosis paraneoplastica is an infrequent paraneoplastic disease in which cutaneous lesions appear and develop in a context of an underlying malignancy. Upper aerodigestive tract carcinomas are the most common neoplasias associated with this syndrome. The aim of this report is to raise awareness of this syndrome, since the recognition of the skin lesions could allow suspicion and diagnosis of the underlying neck malignancy at an early curable stage. Methods: We report a case of a 62-year-old life-long smoking male who presented a several months evolution of multiple skin lesions, affecting both ear lobes, hands and feet. He was referred for appropriate diagnosis and treatme…

medicine.medical_specialtybusiness.industryParaneoplastic diseaseContext (language use)Malignancymedicine.diseaseLaryngeal squamous cell carcinomalcsh:OtorhinolaryngologyDermatologylcsh:RF1-547030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineUpper aerodigestive tractOtorhinolaryngology030220 oncology & carcinogenesismedicineAcrokeratosis paraneoplasticaStage (cooking)Skin lesionbusinessOtolaryngology Case Reports
researchProduct

TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma

2005

To prospectively evaluate the prognostic significance of TP53, H-, K-, and N-Ras mutations, DNA-ploidy and S-phase fraction (SPF) in patients affected by locally advanced laryngeal squamous cell carcinoma (LSCC). Eight-one patients (median follow-up was 71 months) who underwent resective surgery for primary operable locally advanced LSCC were analyzed. Tumor DNA was screened for mutational analysis by PCR/SSCP and sequencing. DNA-ploidy and SPF were performed by flow cytometric analyses. Thirty-six patients (44%) had, at least, a mutation in the TP53 gene. Of them, 22% (8/36) had double mutations and 3% (1/36) had triple mutations. In total, 46 TP53 mutations were observed. The majority (41…

squamous cell carcinomasingle strand conformation polymorphismPrognosipolymerase chain reactionDNA Mutational AnalysisEMTREE drug terms: protein p53 EMTREE medical terms: advanced cancerS PhaseDNA Mutational AnalysiHumansprotein p53 advanced cancer; article; cell cycle S phase; DNA content; exon; flow cytometry; follow up; gene; gene mutation; genetic analysis; histopathology; human; human tissue; larynx carcinoma; multivariate analysis; ploidy; polymerase chain reaction; priority journal; prospective study; single strand conformation polymorphism; squamous cell carcinoma; tp53 gene Carcinoma Squamous Cell; DNA Mutational Analysis; DNA Neoplasm; Genes ras; Humans; Laryngeal Neoplasms; Mutation; Ploidies; Polymorphism Single-Stranded Conformational; Prognosis; S Phase; Survival Rate; Tumor Suppressor Protein p53 [EMTREE drug terms]follow uplarynx carcinomatp53 gene MeSH: Carcinoma Squamous Cellexongene mutationhumanmultivariate analysigeneLaryngeal NeoplasmsPolymorphism Single-Stranded ConformationalLaryngeal NeoplasmPloidiesflow cytometryarticleploidyDNA NeoplasmPrognosisGenes rahuman tissueSurvival RateGenes rascell cycle S phasepriority journalDNA contentgenetic analysiMutationCarcinoma Squamous CellhistopathologyTumor Suppressor Protein p53Ploidieprospective study
researchProduct